Clinical trials: Optic Neuropathy
Traumatic Optic Neuropathy
Surgery for Traumatic Optic Neuropathy
The pathophysiology of Traumatic Optic Neuropathy (TON) include a primary and secondary mechanism of injury. At present, no studies validate a particular approach to the management of TON.
- Trial name
- NCT02711982
- Testing
- Optic canal and optic nerve sheath decompression, methylprednisolone
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Shanghai Changzheng Hospital
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
This phase I/II clinical trial is studying the side effects and best dose of gamma-secretase inhibitor RO4929097 and to see how well it works in treating young patients with relapsed or refractory solid tumors, CNS tumors…
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor
- Trial name
- NCT01088763
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, diagnostic laboratory biomarker analysis, pharmacological study
- Where
- 12 sites in United States, Canada
- Volunteers
- 129 people
- Sponsor
- National Cancer Institute (NCI)
NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)
Outcomes of Steroid and Oxygen Therapy Versus Placebo Therapy in Non-arteritic Anterior Ischemic Optic Neuropathy
Patients diagnosed with NAION within 14 days of onset were included. Patients were randomized into 3 groups. Group 1 or control consisted of 30 patients who received gelatinous capsules filled with sugar as placebo.
- Trial name
- NAION (NCT02439866)
- Testing
- Intravenous methylprednisolone, normobaric oxygen with face mask
- Where
- Iran
- Volunteers
- 90 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma
This phase I trial is studying the side effects and best dose of ispinesib in treating young patients with relapsed or refractory solid tumors or lymphoma.
- Conditions
- Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma
- Trial name
- NCT00363272
- Testing
- ispinesib, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Autosomal Dominant Optic Atrophy, Optic Atrophy, Autosomal Dominant
Natural History of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation
The purpose of this study is to characterize the disease progression of confirmed OPA1 mutation-associated autosomal dominant optic atrophy (ADOA) by evaluating the changes in ocular structural and functional outcomes.
- Conditions
- Autosomal Dominant Optic Atrophy, Optic Atrophy, Autosomal Dominant, Optic Atrophies, Hereditary, Kjer Optic Atrophy
- Trial name
- NCT06140329
- Where
- 7 sites in United States, Australia and 4 more
- Volunteers
- 1 people
- Sponsor
- PYC Therapeutics
Dysthyroid Orbitopathy
Morphometric Analysis of Orbital Structures in Graves´ Orbitopathy
The purpose of this protocol is to study orbital structures in Graves´ Disease using multidetector computed tomography and color doppler imaging.
- Trial name
- NCT00665795
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- University of Sao Paulo
Leber Hereditary Optic Neuropathy
Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year
The goal of this clinical trial is to assess the efficacy and safety of GS010 gene therapy - (lenadogene nolparvovec) in subjects with LHON due to the G11778A ND4 mitochondrial mutation with a vision loss up to one year.
- Trial name
- REFLECT (NCT03293524)
- Testing
- GS010
- Where
- 13 sites in United States, Belgium and 5 more
- Volunteers
- 98 people
- Sponsor
- GenSight Biologics
Primary Open Angle Glaucoma, Normal Tension Glaucoma
Advanced Glycation End Products as a Biomarker for Accelerated Ageing
Globally primary open angle glaucoma (POAG) affects over 60 million people. The exact pathogenesis of POAG is poorly understood. A significant risk factor for glaucoma is advancing age.
- Conditions
- Primary Open Angle Glaucoma, Normal Tension Glaucoma, Ocular Hypertension
- Trial name
- NCT02863224
- Where
- United Kingdom
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- University of Plymouth
Optic Nerve Glioma
Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma
Primary Objectives To compare progression free survival (PFS), the time from randomization to progressive disease,in children with optic pathway glioma (OPG) age ≥ 6 months to < 18 years, who receive combination antineoplaston…
- Trial name
- NCT01260103
- Testing
- Temozolomide, ANP Therapy
- Sponsor
- Burzynski Research Institute
Glaucoma
Repetitive Transcranial Alternating Current Stimulation (rtACS) for the Treatment of Optic Neuropathies
The goal of this study is to see whether repeated transcranial alternating current stimulation can activate impaired retinal ganglion cells and improve both structural and functional outcomes in patients with glaucoma.
- Trial name
- NCT07145073
- Testing
- DC-Stimulator MC
- Where
- Taiwan
- Volunteers
- 188 people
- Sponsor
- National Taiwan University Hospital
Brain and Central Nervous System Tumors, Intraocular Melanoma
Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin)
- Trial name
- NCT00003022
- Testing
- iodine I 131 monoclonal antibody 3F8
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Normal Tension Glaucoma
Deep Sclerectomy Versus Trabeculectomy in Normal Tension Glaucoma
The purpose of this study is to assess whether deep sclerectomy is as effective in lowering intraocular pressure (IOP) as trabeculectomy in patients with normal tension glaucoma.
- Trial name
- DSTRENTG (NCT05371977)
- Testing
- Trabeculectomy, Deep Sclerectomy
- Where
- Finland
- Volunteers
- 80 people
- Sponsor
- Helsinki University Central Hospital
Glaucoma, Open-Angle, Normal Tension Glaucoma
Investigation of Neurovascular Coupling in Glaucoma Patients and Healthy Subjects
Glaucoma is characterized by a progressive loss of retinal ganglion cells (RGCs) leading to optic nerve head (ONH) damage and associated visual field defects.
- Conditions
- Glaucoma, Open-Angle, Normal Tension Glaucoma, Ocular Hypertension
- Trial name
- NCT03870230
- Testing
- Fourier Domain Doppler Optical Coherence Tomography (FDOCT), Dynamic Vessel Analyzer (DVA), Pattern Electroretinography (pERG)
- Where
- Austria
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Optic Neuritis
Effect of Phenytoin on the Ganglion Cell Layer in Patients With Optic Neuritis
Optic neuritis typically occurs in young (mean age, 32 years), female (77%) patients, and it presents as subacute monocular visual loss that develops over several days.
- Trial name
- NCT02939937
- Testing
- Phenytoin
- Where
- Iran
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Tehran University of Medical Sciences
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Maintenance Plasma Exchange for Neuromyelitis Optica
Neuromyelitis optica (NMO) is an inflammatory disease of the central nervous system that is associated with autoantibodies to aquaporin-4.
- Conditions
- Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, Recurrent Idiopathic Longitudinally Extensive Transverse Myelitis
- Trial name
- MultiPLEX (NCT01500681)
- Testing
- Plasma exchange (PLEX)
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Mayo Clinic
Biotin Deficiency, Optic Neuropathy
BIOtinidase Test In Optic-Neuropathy
Biotinidase is an enzyme that recycles biotin, a water-soluble vitamin essential as a coenzyme for four carboxylases that are involved in gluconeogenesis, fatty acid synthesis, and in the catabolism of several branch-chain amino…
- Trial name
- BIOTIN (NCT03268681)
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Optic Nerve Diseases, Optic Nerve Injuries
Paraorbital-Occipital Alternating Current Stimulation Therapy for Optic Neuropathy (MCT_optnerve)
Aim is to validate that non-invasive brain stimulation can increase cortical excitability in the visual system. The investigators assess if transcranial alternating current stimulation (tACS) can improve visual field size in…
- Conditions
- Optic Nerve Diseases, Optic Nerve Injuries, Optic Neuropathies
- Trial name
- NCT01280877
- Testing
- tACS
- Where
- 4 sites in Germany
- Volunteers
- 90 people
- Sponsor
- University of Magdeburg
Multiple Sclerosis, Neuromyelitis Optica
MS and NMOSD in African-Americans
This is a prospective study that aims to collect and review neuromyelitis optica spectrum disorder (NMOSD) data from African American patients with a known diagnosis of multiple sclerosis (MS).
- Trial name
- NCT04131673
- Where
- United States
- Sponsor
- Jagannadha R Avasarala
Neuromyelitis Optica Spectrum Disorder, NMOSD
A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
This study will primarily evaluate the pharmacokinetics of satralizumab in pediatric patients aged 2-11 years with anti-aquaporin-4 (AQP4) antibody seropositive neuromyelitis optica spectrum disorder (NMOSD).
- Trial name
- SAkuraSun (NCT05199688)
- Testing
- Satralizumab
- Where
- 14 sites in United States, Argentina and 7 more
- Volunteers
- 8 people
- Sponsor
- Hoffmann-La Roche
Leber Hereditary Optic Neuropathy
Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON)
This study is meant to assess the safety and efficacy of rAAV2-ND4 treatment of Leber hereditary optic neuropathy with 11778 LHON mutation.
- Trial name
- rAAV2-ND4 (NCT01267422)
- Testing
- rAAV2-ND4
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Bin Li